2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183567
    Ferroptosis-IN-27 3030492-72-6
    Ferroptosis-IN-27 is a glutathione peroxidase (GPx) mimetic. Ferroptosis-IN-27 inhibits oxidative stress, reduces intracellular ROS levels, decreases lipid peroxidation and alleviates ferrous ion overload, thereby inhibiting ferroptosis and protecting cardiomyocytes from Doxorubicin (HY-15142A)-induced injury. Ferroptosis-IN-27 can be used in studies related to Doxorubicin-induced cardiotoxicity.
    Ferroptosis-IN-27
  • HY-183629
    ZNF281-IN-1
    ZNF281-IN-1 is a ZNF281 inhibitor. ZNF281-IN-1 disrupts the binding of transcriptionally active DNA-bound ZNF281 to the promoters of target genes including TRIM35 and ZEB1. ZNF281-IN-1 inhibits tumor cell proliferation, stabilizes P53 and upregulates PUMA to induce apoptosis, while triggering cellular senescence. ZNF281-IN-1 completely prevents Doxorubicin (HY-15142A)-induced cardiotoxicity (AIC), and enhances rather than impairs the antitumor efficacy of Doxorubicin. ZNF281-IN-1 completely blocks the distant metastasis of melanoma to the lungs. ZNF281-IN-1 can be used in the research of cardiotoxicity, lung cancer and metastatic melanoma.
    ZNF281-IN-1
  • HY-183636
    M353-0039 1185074-29-6
    M353-0039 is a selective UT-A2 inhibitor with a human IC50 of 0.35 μM. M353-0039 blocks urea transport mediated by UT-A2. M353-0039 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis.
    M353-0039
  • HY-183637
    E822-1968 1037259-63-4
    E822-1968 is an UT-A2 inhibitor with a human IC50 of 0.44 μM. E822-1968 blocks urea transport mediated by UT-A2. E822-1968 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis.
    E822-1968
  • HY-183644
    LNO 9 98%
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension.
    LNO 9
  • HY-183654
    Vadadustat prodrug-1
    Vadadustat prodrug-1 is a near-infrared activated photocaged, blood-brain barrier-permeable neuroprotective prodrug of Vadadustat. Vadadustat prodrug-1 masks the acidic pharmacophore of Vadadustat, and releases active Vadadustat upon irradiation at 650 nm to inhibit PHD2. Vadadustat prodrug-1 reduces cell damage, infarct volume and cerebral edema, and promotes neurological function recovery. Vadadustat prodrug-1 can be used for the research of ischemic stroke.
    Vadadustat prodrug-1
  • HY-183692
    FXR agonist 18 3061938-00-6 98%
    FXR agonist 18 is an orally active FXR agonist, with an EC50 of 10 nM against human FXR and an EC50 of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis.
    FXR agonist 18
  • HY-183777
    B-007
    B-007 is an AplnR agonist with G protein-biased signaling (EC50 = 11.6 nM). B-007 activates the G protein pathway while abolishing β-arrestin1 and β-arrestin2 signaling. B-007 serves as a scaffold for development of G protein-biased apelin receptor agonists. B-007 can be used for the research of heart failure.
    B-007
  • HY-183836
    FABP4/5-IN-7 1227413-92-4
    FABP4/5-IN-7 is a dual FABP4/FABP5 inhibitor, with an IC50 of 0.8 μM and a Kd of 0.01 μM for FABP4, and an IC50 of 1.4 μM for FABP5. FABP4/5-IN-7 inhibits lipolysis in adipocytes. FABP4/5-IN-7 inhibits MCP-1 release in macrophages. FABP4/5-IN-7 improves dyslipidemia in diet-induced obese mice. FABP4/5-IN-7 can be used in studies related to dyslipidemia.
    FABP4/5-IN-7
  • HY-183906
    GSK3491943 2215853-96-4
    GSK3491943 is an antagonist of the transient receptor potential vanilloid subtype 4 (TRPV4) ion channel. GSK3491943 is applicable to research related to pulmonary edema induced by heart failure.
    GSK3491943
  • HY-183982
    PAR4 antagonist 9-phosphoric acid 2173066-81-2
    PAR4 antagonist 9-phosphoric acid is a phosphate prodrug of the PAR4 antagonist 9 (HY-183983). PAR4 antagonist 9-phosphoric acid is applicable to research related to arterial thrombosis.
    PAR4 antagonist 9-phosphoric acid
  • HY-183983
    PAR4 antagonist 9 2173066-25-4
    PAR4 antagonist 9 is an orally active protease-activated receptor 4 (PAR4) antagonist with an IC50 of 2 nM against human targets. PAR4 antagonist 9 functionally modulates PAR4 and inhibits platelet aggregation. PAR4 antagonist 9 can be used in studies related to arterial thrombosis.
    PAR4 antagonist 9
  • HY-183985
    Hsp110/HDAC6-IN-1
    Hsp110/HDAC6-IN-1 is an orally active Hsp110/HDAC6 dual inhibitor. Hsp110/HDAC6-IN-1 disrupts Hsp110-STAT3 protein-protein interaction, suppresses HDAC6 enzymatic activity, and suppresses STAT3 signaling pathway. Hsp110/HDAC6-IN-1 inhibits abnormal proliferation and migration of human pulmonary arterial endothelial cells, and suppresses pulmonary vascular remodeling in rats. Hsp110/HDAC6-IN-1 can be used for the research of pulmonary arterial hypertension.
    Hsp110/HDAC6-IN-1
  • HY-184089
    ATB1071 2921556-65-0 98%
    ATB1071 is a brain-penetrant and orally active p62/SQSTM1 activator. ATB1071 binds to the p62-ZZ domain, promotes PB1-dependent p62 self-polymerization, and activates p62-mediated mitophagy. ATB1071 can be used for the research of Leigh syndrome, cerebral ischemia-reperfusion injury[1].
    ATB1071
  • HY-184115
    JHB-17
    JHB-17 is an IKKβ inhibitor with blood-brain barrier permeability, with an IC50 of 1.1 μM and a KD of 1.293 μM. JHB-17 is a non-ATP competitive inhibitor targeting the allosteric site of IKKβ, and it inhibits the phosphorylation of IKKβ. JHB-17 promotes the nuclear translocation of Nrf2, upregulates the expression of HO-1, SLC7A11 and glutathione, and reduces ROS to exert antioxidant effects. JHB-17 reduces cerebral infarction volume and improves neurobehavioral function. JHB-17 can be used in the research of cerebral ischemia-reperfusion injury.
    JHB-17
  • HY-184190
    ERG-IN-7
    ERG-IN-7 is a Nav1.5, Cav1.2 and Kv11.1 inhibitor with IC50 values of 10.34 μM, 21.01 μM, and 16.385 μM for human Nav1.5, Cav1.2, and Kv11.1, respectively. ERG-IN-7 prolongs action potentials, reduces conduction velocity, and restores cardiac function. ERG-IN-7 can be used for the research of ventricular arrhythmia.
    ERG-IN-7
  • HY-184207
    Zinc13732787 119486-83-8
    Zinc13732787 is an inhibitor of the KCNQ1/KCNE1 potassium channel complex, with no activity against the KCNQ2/KCNQ3 channel. Zinc13732787 reduces axonal growth in human neural stem cells, while exerting no effect on KCNQ1-knockout neural stem cells. Zinc13732787 can be used for research on arrhythmia, epilepsy, and neuropsychiatric disorders.
    Zinc13732787
  • HY-185008
    CPP11G 1580464-93-2
    CPP11G (Compound 11g) is a highly selective NADPH oxidase 2 (Nox2) inhibitor (IC50=20 μM). CPP11G is promising for research of inflammatory diseases (e.g., vasculitis, atherosclerosis) and Nox2-overactivated pathologies (e.g., ischemia-reperfusion injury).
    CPP11G
  • HY-185056
    Ferfluor-1 3030473-59-4 99.33%
    Ferfluor-1 is a Ferroptosis inhibitor (EC50 of 57 nM in HT108 cells; EC50 of 75 nM in OS-RC-2 cells; EC50 of 2.3 nM in SH-SY5Y neuroblastoma cells), and ratiometric photoluminescent probe with blood-brain barrier permeability. Ferfluor-1 is a specific indicator for the fluctuation of Ferroptosis. Ferfluor-1 alleviates brain disorder diseases of in vivo stroke and PD models.
    Ferfluor-1
  • HY-185133
    RBP4-IN-3 3107328-23-1 98%
    RBP4-IN-3 (Compound 38) is a retinol-binding protein 4 (RBP4) inhibitor. RBP4-IN-3 can be used in studies related to cardiovascular diseases and obesity.
    RBP4-IN-3
Cat. No. Product Name / Synonyms Application Reactivity